UK markets close in 2 hours 28 minutes
  • FTSE 100

    6,537.28
    -114.68 (-1.72%)
     
  • FTSE 250

    21,023.45
    -174.67 (-0.82%)
     
  • AIM

    1,183.17
    -8.69 (-0.73%)
     
  • GBP/EUR

    1.1515
    +0.0017 (+0.15%)
     
  • GBP/USD

    1.3964
    -0.0049 (-0.35%)
     
  • BTC-GBP

    33,158.99
    -3,702.17 (-10.04%)
     
  • CMC Crypto 200

    924.14
    -9.00 (-0.96%)
     
  • S&P 500

    3,829.34
    -96.09 (-2.45%)
     
  • DOW

    31,402.01
    -559.85 (-1.75%)
     
  • CRUDE OIL

    62.48
    -1.05 (-1.65%)
     
  • GOLD FUTURES

    1,760.60
    -14.80 (-0.83%)
     
  • NIKKEI 225

    28,966.01
    -1,202.26 (-3.99%)
     
  • HANG SENG

    28,980.21
    -1,093.96 (-3.64%)
     
  • DAX

    13,807.14
    -72.19 (-0.52%)
     
  • CAC 40

    5,721.66
    -62.23 (-1.08%)
     

Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million € contribution to sales in 2021

·2-min read

Dermapharm Holding SE / Key word(s): Development of Sales
Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million € contribution to sales in 2021

12-Feb-2021 / 13:05 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Disclosure of Insider Information pursuant to Section 17 (1) 1 of the Regulation (EU)
No. 596/2014 on Market Abuse, as amended
(Market Abuse Regulation - MAR)

Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million € contribution to sales in 2021

Grünwald, February 12, 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) expects the cooperation with BioNTech SE, Mainz, in the production of the Covid-19 vaccine Comirnaty(R) to contribute a high double-digit million € amount to the consolidated sales of the Dermapharm Group in the full year 2021. This is the result of a current plan for vaccine production approved today by the Management Board of Dermapharm Holding SE. Among other things, it includes the establishment of additional production capacities at the Reinbek site, which are scheduled to go into operation in May 2021.

>End of the ad hoc announcement<

Contacts

Investor Relations &
Corporate Communications
Britta Hamberger
Phone: +49 (0)89 - 64186-233
Fax: +49 (0)89 - 64186-165
e-Mail: ir@dermapharm.com

cometis AG
Claudius Krause
Phone: +49 (0)611 - 205855-28
Fax: +49 (0)611 - 205855-66
e-Mail: ir@dermapharm.com

 

 

 

12-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Dermapharm Holding SE

Lil-Dagover-Ring 7

82031 Grünwald

Germany

Phone:

+49 (0)89 64 86-0

E-mail:

ir@dermapharm.com

Internet:

ir.dermapharm.de

ISIN:

DE000A2GS5D8

WKN:

A2GS5D

Indices:

SDAX

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange

EQS News ID:

1167965


 

End of Announcement

DGAP News Service

show this
show this